Seeking Alpha

Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating...

Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating people with amyotrophic lateral sclerosis (ALS), which is also known as Lou Gehrig's disease and which affects the nerve cells in the brain and spinal cord that control muscle movement. The medicine didn't meet its primary goals of improving "function and survival," nor did it meet any key secondary endpoints. (PR)
Comments (2)
  • stevesko
    , contributor
    Comments (51) | Send Message
     
    Over reaction, they have a strong pipeline, and when doing drug discovery these things should be expected. It's not like it was BG-12 that failed, THAT would cause the stock to tank.
    3 Jan 2013, 08:58 AM Reply Like
  • hagof
    , contributor
    Comment (1) | Send Message
     
    My sister has MS and I have invested in BIIB while it was still Biogen.
    I am not ready to give up, some drugs will eventually be effective, research is a long term project.
    Hadwig (Chemist)
    3 Jan 2013, 11:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|